SEARCH

SEARCH BY CITATION

References

  • 1
    Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 11511164.
  • 2
    Thornton A, Shevach EM. CD4+CD25+ Immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998; 188: 287296.DOI: 10.1084/jem.188.2.287
  • 3
    Lin CY, Graca L, Cobbold SP, Waldmann H. Dominant transplantation tolerance impairs CD8+ T cell function but not expansion. Nat Immunol 2002; 3: 12081213.DOI: 10.1038/ni853
  • 4
    Van Maurik A, Herber M, Wood KJ, Jones ND. Cutting edge: CD4+CD25+ alloantigen-specific immunoregulatory cells that can prevent CD8+ T cell-mediated graft rejection: implications for anti-CD154 immunotherapy. J Immunol 2002; 169: 54015404.
  • 5
    Camara NO, Sebille F, Lechler RI. Human CD4+CD25+ regulatory cells have marked and sustained effects on CD8+ T cell activation. Eur J Immunol 2003; 33: 34733483.DOI: 10.1002/eji.200323966
  • 6
    Hara M, Kingsley CI, Niimi M, Read S, Turvey SE, Bushell AR et al.. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001; 166: 37893796.
  • 7
    Kingsley CI, Karim M, Bushell AR, Wood KJ. CD25+CD4+ Regulatory T cells Prevent Graft Rejection: CTLA-4 and IL10 Dependent Immunoregulation of Alloresponses. J Immunol 2002; 18: 10801086.
  • 8
    Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex Vivo Isolation and Characterization of CD4+CD25+ T cells with Regulatory Properties from Human Blood. J Exp Med 2001; 193: 13031310.DOI: 10.1084/jem.193.11.1303
  • 9
    Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characteristics of human CD4+CD25+ T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193: 12851294.DOI: 10.1084/jem.193.11.1285
  • 10
    Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, Edwards AD et al.. Human CD4+CD25+ T cells: a naturally occuring population of regulatory T cells. Blood 2001; 98: 27362744.
  • 11
    Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN. Human/ anergic suppressive CD4+CD25+ T cells: a highly differentiated and apoptosis prone population. Eur J Immunol 2001; 31: 11221131.DOI: 10.1002/1521-4141(200104)31:4<1122::AID-IMMU1122>3.0.CO;2-P
  • 12
    Taams LS, Vukmanovic-Stejic M, Smith J, Dunne PJ, Fletcher JM, Plunkett FJ et al.. Antigen-specific T cell suppression by human CD4+CD25+ regulatory T cells. Eur J Immunol 2002; 32: 16211630.DOI: 10.1002/1521-4141(200206)32:6<1621::AID-IMMU1621>3.0.CO;2-Q
  • 13
    Salama AD, Najafian N, Clarkson MR, Harmon WE, Sayegh MH. Regulatory CD25+ T cells in human kidney transplant recipients. J Am Soc Nephrol. 2003; 14: 16431651.DOI: 10.1097/01.ASN.0000057540.98231.C1
  • 14
    Game DS, Hernandez-Fuentes MP, Chaudhry AN, Lechler RI. CD4+CD25+ regulatory T cells do not significantly contribute to direct pathway hyporesponsiveness in stable renal transplant patients. J Am Soc Nephrol 2003; 14: 16521661.DOI: 10.1097/01.ASN.0000067411.03024.A9
  • 15
    Jiang S, Camara NOS, Lombardi G, Lechler RI. Induction of Allopeptide-Specific Human CD4+CD25+ Regulatory T cells Ex-vivo. Blood 2003b; 102: 21802186.
  • 16
    Amlot PL, Rawlings E, Fernando ON, Griffin PJ, Heinrich G, Schreier MH et al.. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995; 60: 748756.
  • 17
    Webster AC, Playford GE, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomised trials. Transplantation 2004; 77: 166176.DOI: 10.1097/01.TP.0000109643.32659.C4
  • 18
    Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 1990; 144: 251258.
  • 19
    Schuler W, Sedrani R, Cottens S, Haberlin B, Schulz M, Schuurman HJ et al.. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 3642.DOI: 10.1097/00007890-199707150-00008
  • 20
    Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P et al.. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 10361042.DOI: 10.1097/00007890-199904150-00017
  • 21
    Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777786.DOI: 10.1097/00007890-200109150-00007
  • 22
    Kahan BD, Kaplan B, Lorber MI, Winkler M, Cambon N, Boger RS. RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation 2001; 71: 14001406.DOI: 10.1097/00007890-200105270-00008
  • 23
    DeSilva DR, Urdahl KB, Jenkins MK. Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation. J Immunol 1991; 147: 32613267.
  • 24
    Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999a; 5: 12981302.DOI: 10.1038/15256
  • 25
    Wells AD, Li XC, Li Y, Walsh MC, Zheng XX, Wu Z et al.. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999; 5: 13031307.DOI: 10.1038/15260
  • 26
    Smiley ST, Csizmadia V, Gao W, Turka LA, Hancock WW. Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: implications for tolerance induction. Transplantation 2000; 70: 415419.DOI: 10.1097/00007890-200008150-00005
  • 27
    Wekerle T, Kurtz J, Sayegh M, Ito H, Wells A, Bensinger S et al.. Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death. J Immunol 2001; 166: 23112316.
  • 28
    Macian F, Garcia-Cozar F, Im S-H, Horton HF, Byrne MC, Rao A. Transcriptional Mechanisms Underlying Lymphocyte Tolerance. Cell 2002; 109: 719731.
  • 29
    Papiernik M, De Moraes ML, Pontoux C, Vasseur F, Penit C. Regulatory CD4 T cells: expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency. Int Immunol 1998; 10: 371378.DOI: 10.1093/intimm/10.4.371
  • 30
    Furtado GC, Curotto de Lafaille MA, Kutchukhidze N, Lafaille JJ. Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J Exp Med 2002; 196: 851857.DOI: 10.1084/jem.20020190
  • 31
    Baecher-Allan C, Viglietta V, Hafler DA. Inhibition of human CD4(+)CD25(+high) regulatory T cell function. J Immunol 2002; 169: 62106217.
  • 32
    Game DS, Lechler RI. HLA-DR matching and immune regulation. Am J Transplant 2004; 4: 17251726.DOI: 10.1111/j.1600-6143.2004.00570.x
  • 33
    Rowshani AT, Uss A, Yong SL, Van Lier RA, Ten Berge IJ. Effects of CD25 monoclonal antibody on proliferative and effector functions of alloactivated human T cells in vitro. Eur J Immunol 2004; 34: 882899.DOI: 10.1002/eji.200324821
  • 34
    Koenen HJ, Fasse E, Joosten I. IL-15 and cognate antigen successfully expand de novo-induced human antigen-specific regulatory CD4(+) T cells that require antigen-specific activation for suppression. J Immunol 2003; 171: 64316441.
  • 35
    Kupiec-Weglinski JW, Filho MA, Strom TB, Tilney NL. Sparing of suppressor cells: a critical action of cyclosporine. Transplantation 1984; 38: 97101.
  • 36
    Kircher B, Latzer K, Gastl G, Nachbaur D. Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti-CD25 monoclonal antibodies. Clin Exp Immunol 2003; 134: 426430.DOI: 10.1111/j.1365-2249.2003.02324.x
  • 37
    Baan CC, Van Gelder T, Balk AHMM, Knoop CJ, Holweg CTJ, Maat LPWM et al.. Functional responses of T cells blocked by anti-CD25 antibody therapy during cardiac rejection. Transplantation 2000; 69: 331336.
  • 38
    Zheng XX, Sanchez-Fueyo A, Sho M, Domenig C, Sayegh MH, Strom TB. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 2003a; 19: 503514.DOI: 10.1016/S1074-7613(03)00259-0
  • 39
    Tian L, Lu L, Yuan Z, Lamb JR, Tam PK. Acceleration of apoptosis in CD4+CD8+ thymocytes by rapamycin accompanied by increased CD4+CD25+ T cells in the periphery. Transplantation 2004; 77: 183189.DOI: 10.1097/01.TP.0000101005.44661.3E
  • 40
    Banz A, Pontoux C, Papiernik M. Modulation of Fas-dependent apoptosis: a dynamic process controlling both the persistence and death of CD4 regulatory T cells and effector T cells. J Immunol 2002; 169: 750757.
  • 41
    Waldmann TA. A novel means of favorably tipping the balance between cytopathic and regulatory T cells. Immunity 2003; 19: 465466.DOI: 10.1016/S1074-7613(03)00273-5
  • 42
    Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25+high Regulatory Cells in Human Peripheral Blood. J Immunol 2001; 167: 12451253.
  • 43
    Bensinger SJ, Walsh PT, Zhang J, Carroll M, Parsons R, Rathmell J et al.. Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J Immunol 2004; 172: 52875296.
  • 44
    Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R et al.. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98: 1003110033.DOI: 10.1073/pnas.191379498
  • 45
    McDyer JF, Li Z, John S, Yu X, Wu CY, Ragheb JA. IL-2 receptor blockade inhibits late, but not early, IFN-gamma and CD40 ligand expression in human T cells: disruption of both IL-12–dependent and -independent pathways of IFN-gamma production. J Immunol 2002; 169: 27362746.
  • 46
    Matsue H, Yang C, Matsue K, Edelbaum D, Mummert M, Takashima A. Contrasting impacts of immunosuppressive agents (rapamycin, FK506, cyclosporin A, and dexamethasone) on bidirectional dendritic cell-T cell interaction during antigen presentation. J Immunol 2002; 169: 35553564.
  • 47
    Chiang PH, Wang L, Bonham CA, Liang X, Fung JJ, Lu L et al.. Mechanistic insights into impaired dendritic cell function by rapamycin: inhibition of Jak2/Stat4 signaling pathway. J Immunol 2004; 172: 13551363.